• Mangoceuticals priced a private placement of 850,000 restricted common shares at USD 0.32 per share, raising USD 272,000.
• The sale closed June 29, 2026 with an accredited investor under Section 4(a)(2) and/or Rule 506 of Regulation D.
• The investor received piggyback registration rights for one year from the subscription dates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031917), on July 02, 2026, and is solely responsible for the information contained therein.